Drug Profile
BBT 877
Alternative Names: BBT-877Latest Information Update: 01 Apr 2024
Price :
$50
*
At a glance
- Originator LegoChem Biosciences
- Developer Bridge Biotherapeutics
- Class Antifibrotics; Small molecules
- Mechanism of Action ENPP2 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Idiopathic pulmonary fibrosis
Most Recent Events
- 01 Apr 2024 Bridge Biotherapeutics and Dr. Jessica Konen's Lab plans to conduct preclinical studies for BBT-877 for Solid tumours
- 29 Mar 2024 Bridge Biotherapeutics enters into collaboration agreement with Emory University School of Medicine to explore combination therapy of BBT-877
- 26 Mar 2024 Bridge Biotherapeutics enters into a research collaboration with University of Colorado School of Medicine for Cancer